Buprenorphine exposure in infants of opioid-dependent mothers at birth
Background: Buprenorphine, a partial opioid agonist used in treating opioid dependence, is not approved in Australia for use in pregnancy. Nevertheless, many pregnant women choose to remain on the drug. Aim: To investigate cord/maternal transfer ratios for buprenorphine and norbuprenorphine in women...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Wiley-Blackwell Publishing Asia
2012
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/23459 |
| _version_ | 1848751157331099648 |
|---|---|
| author | Bartu, Anne Ilett, K. Hackett, L. Doherty, D. Hamilton, D. |
| author_facet | Bartu, Anne Ilett, K. Hackett, L. Doherty, D. Hamilton, D. |
| author_sort | Bartu, Anne |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Background: Buprenorphine, a partial opioid agonist used in treating opioid dependence, is not approved in Australia for use in pregnancy. Nevertheless, many pregnant women choose to remain on the drug. Aim: To investigate cord/maternal transfer ratios for buprenorphine and norbuprenorphine in women at delivery. Methods: Maternal and cord serum samples were collected from 10 maternal-infant pairs at delivery. Drug concentrations were measured by liquid chromatography-tandem mass spectrometry. Maternal and infant demographic information was collected. Linear regression was used to assess the relationship between maternal and cord measurements. Results: Median (interquartile range) maternal age was 27 (23.8–32) years, with 90% of the women on buprenorphine before pregnancy. Median infant birthweight was 3148 (3088–3545) g and 60% of infants had neonatal abstinence requiring admission to a neonatal intensive care unit for a median of 8.5 (2.5–16.3) days. Median maternal buprenorphine daily dose was 8.5 mg (range 1–28 mg). Mean (95% confidence interval) cord serum concentrations of buprenorphine and norbuprenorphine were 0.4 (0.3–0.5) μg/L and 1.2 (0.9–1.4) μg/L, respectively. Mean maternal concentrations of buprenorphine and norbuprenorphine were 1.0 (0.6–1.4) μg/L and 1.2 (0.9–1.4) μg/L, respectively. Mean cord/maternal ratios were 0.43 (0.36–0.5) for buprenorphine and 0.53 (0.43–0.63) for norbuprenorphine. Maternal buprenorphine and norbuprenorphine concentrations and ratio of buprenorphine/norbuprenorphine explained 85.7, 69.6 and 94.4%, respectively, of variation in the corresponding cord concentrations. Conclusion: Usual therapeutic doses of buprenorphine administered to pregnant women resulted in low concentrations of buprenorphine and norbuprenorphine in maternal serum and a low transfer to the fetal circulation (cord plasma) at birth. |
| first_indexed | 2025-11-14T07:48:16Z |
| format | Journal Article |
| id | curtin-20.500.11937-23459 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T07:48:16Z |
| publishDate | 2012 |
| publisher | Wiley-Blackwell Publishing Asia |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-234592017-09-13T15:59:55Z Buprenorphine exposure in infants of opioid-dependent mothers at birth Bartu, Anne Ilett, K. Hackett, L. Doherty, D. Hamilton, D. buprenorphine infant exposure at delivery norbuprenorphine placental transfer Background: Buprenorphine, a partial opioid agonist used in treating opioid dependence, is not approved in Australia for use in pregnancy. Nevertheless, many pregnant women choose to remain on the drug. Aim: To investigate cord/maternal transfer ratios for buprenorphine and norbuprenorphine in women at delivery. Methods: Maternal and cord serum samples were collected from 10 maternal-infant pairs at delivery. Drug concentrations were measured by liquid chromatography-tandem mass spectrometry. Maternal and infant demographic information was collected. Linear regression was used to assess the relationship between maternal and cord measurements. Results: Median (interquartile range) maternal age was 27 (23.8–32) years, with 90% of the women on buprenorphine before pregnancy. Median infant birthweight was 3148 (3088–3545) g and 60% of infants had neonatal abstinence requiring admission to a neonatal intensive care unit for a median of 8.5 (2.5–16.3) days. Median maternal buprenorphine daily dose was 8.5 mg (range 1–28 mg). Mean (95% confidence interval) cord serum concentrations of buprenorphine and norbuprenorphine were 0.4 (0.3–0.5) μg/L and 1.2 (0.9–1.4) μg/L, respectively. Mean maternal concentrations of buprenorphine and norbuprenorphine were 1.0 (0.6–1.4) μg/L and 1.2 (0.9–1.4) μg/L, respectively. Mean cord/maternal ratios were 0.43 (0.36–0.5) for buprenorphine and 0.53 (0.43–0.63) for norbuprenorphine. Maternal buprenorphine and norbuprenorphine concentrations and ratio of buprenorphine/norbuprenorphine explained 85.7, 69.6 and 94.4%, respectively, of variation in the corresponding cord concentrations. Conclusion: Usual therapeutic doses of buprenorphine administered to pregnant women resulted in low concentrations of buprenorphine and norbuprenorphine in maternal serum and a low transfer to the fetal circulation (cord plasma) at birth. 2012 Journal Article http://hdl.handle.net/20.500.11937/23459 10.1111/j.1479-828X.2012.01424.x Wiley-Blackwell Publishing Asia restricted |
| spellingShingle | buprenorphine infant exposure at delivery norbuprenorphine placental transfer Bartu, Anne Ilett, K. Hackett, L. Doherty, D. Hamilton, D. Buprenorphine exposure in infants of opioid-dependent mothers at birth |
| title | Buprenorphine exposure in infants of opioid-dependent mothers at birth |
| title_full | Buprenorphine exposure in infants of opioid-dependent mothers at birth |
| title_fullStr | Buprenorphine exposure in infants of opioid-dependent mothers at birth |
| title_full_unstemmed | Buprenorphine exposure in infants of opioid-dependent mothers at birth |
| title_short | Buprenorphine exposure in infants of opioid-dependent mothers at birth |
| title_sort | buprenorphine exposure in infants of opioid-dependent mothers at birth |
| topic | buprenorphine infant exposure at delivery norbuprenorphine placental transfer |
| url | http://hdl.handle.net/20.500.11937/23459 |